Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
Authors' conclusion
Canagliflozin reduces the risk of kidney and cardiovascular events similarly across geographic regions and racial groups.
Study context
- Population
- Individuals with T2D and CKD, across six geographic regions (North America 1182, Central and South America 941, Eastern Europe 947, Western Europe 421, Asia 749, Other 161) and four racial groups (White 2931, Black or African American 224, Asian 877, Other 369)
- Participants
- 4,401 individuals
- Comparison
- Canagliflozin vs placebo
- Primary endpoint
- Composite of:
- End-stage kidney disease (ESKD)
- Doubling of serum creatinine (SCr)
- Death from kidney or cardiovascular causes
Methodological detailssubgroup analysis by geographic region and racial group, stratified Cox proportional hazards model
- Subgroup analysis by geographic region and racial group
- Stratified Cox proportional hazards model
Primary result
As reported in the abstract
- Canagliflozin consistently reduced the primary composite endpoint across geographic regions without evidence of heterogeneity
- interaction P=0.39
- Canagliflozin consistently reduced the primary composite endpoint across racial groups without evidence of heterogeneity
- interaction P=0.91
Secondary outcomes
Primary composite outcome, overall trial
| HR (95% CI) | P value | ||
|---|---|---|---|
| CanagliflozinRelative risk reduced by 30% | 0.70 (0.59–0.82) | P = 0.00001 | |
| 0.512Hazard ratio (log scale) |
Safety
- No significant safety outcome differences across geographic regions and racial groups
Original publication
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial. Diabetes Obes Metab. Published 19 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →